It has also been shown that lapatinib-induced inhibition of the crosstalk between EGFR/ErbB2 and ER pathways in ErbB2+/ER+ breast cancers is closely linked to its anti-tumor efficacy. This evidence concerns the gene ERBB2 and breast carcinoma.